| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 |
| 14 Oct 2026 | SCHEDULE 13G/A |
| 14 Sep 2026 | SCHEDULE 13G |
| 24 Aug 2026 |
8-K: Other Events
– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication – |
| 19 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Deramiocel Biologics License Application (BLA) under active FDA review |
| 07 Aug 2026 | SCHEDULE 13G |
| 03 Aug 2026 | SCHEDULE 13G |
| 30 Jul 2026 |
8-K: Other Events
SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that the U.S. Food and Drug Admini... |
| 29 Jul 2026 |
8-K: Other Events
--Independent Peer Review Provides External Validation of the Trial's Design, Statistical Methodology and Findings-- |
| 14 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On July 9, 2026, Capricor Therapeutics, Inc. (“Capricor”) entered into a Lease Agreement (the “Lease”) with ARE-SD Region No. 39 Owner, LLC (“Landlord”) for approximately 171,000 rentable square feet located at 9625 Towne Centre Drive, S... |
| 29 Jun 2026 |
Form 4: Krasney Karen, EVP, GENERAL COUNSEL
Received 24,100 shares by exercise or conversion ($76.6K) · Sold 24,100 shares ($732K) |
| 29 Jun 2026 |
Form 4: Bergmann Anthony, CHIEF FINANCIAL OFFICER
Received 24,100 shares by exercise or conversion ($76.6K) · Sold 24,100 shares ($732K) |
| 26 Jun 2026 |
8-K: Other Events
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy |
| 24 Jun 2026 |
Form 4: Krasney Karen, EVP, GENERAL COUNSEL
Received 500 shares by exercise or conversion ($1.59K) · Sold 500 shares ($15K) · Received 400 shares by exercise or conversion ($1.27K) · 1 more |
| 24 Jun 2026 |
Form 4: Bergmann Anthony, CHIEF FINANCIAL OFFICER
Received 500 shares by exercise or conversion ($1.59K) · Sold 500 shares ($15K) · Received 400 shares by exercise or conversion ($1.27K) · 1 more |
Loading...